Alzheimer's disease has long been understood as a problem of toxic protein buildup, but researchers have now identified an unexpected accomplice in the disease's progression: a protein called Arc that normally helps neurons communicate may also be enabling the toxic Tau protein to spread from damaged cells to healthy ones.
The finding, published in Cell, reveals a potential vulnerability that could be exploited to slow or halt the disease before it devastates the brain. Rather than trying to eliminate Tau entirely, scientists are now considering whether blocking its transport between cells could preserve cognitive function in early-stage patients.
In Alzheimer's, the Tau protein accumulates into sticky tangles that clog the neuron's internal machinery and eventually kill the cell. As Tau spreads to neighboring healthy brain tissue, the disease worsens. Researchers at University of Utah Health set out to understand exactly how this transmission happens by studying mice with and without the Arc protein.
The experiments revealed that Arc acts as an unwitting delivery system. Under normal conditions, Arc packages itself inside tiny bubble-like structures called extracellular vesicles, which ferry chemical signals between neurons. But toxic Tau has learned to hitch a ride inside these same vesicles, using Arc's natural communication network to jump from a sick neuron into a healthy one.
When researchers removed Arc from the mice, the transportation of Tau almost vanished. The disease could no longer spread effectively to neighboring cells. Mice lacking Arc showed extracellular vesicles containing very little Tau, compared to the heavy load seen in normal mice.
"When we removed Arc, we saw that the transfer of Tau was severely, severely reduced," said Mitali Tyagi, the study's lead author. "It was almost gone."
Yet the picture is more complicated than simply blocking Arc. The researchers discovered that Arc also serves a protective function in early disease stages. By helping neurons expel excess toxic Tau, Arc allows damaged cells to survive longer. When Arc is absent, Tau becomes trapped inside the original neuron, which then dies faster. This dual role suggests the most effective treatment would not involve shutting down Arc entirely.
Instead, the researchers propose targeting the toxic vesicles after they leave a diseased cell but before they reach healthy tissue. Such an approach could interrupt the disease's spread without disrupting Arc's beneficial functions.
"If we could target these particular vesicles, that would be a really useful therapy strategy," said Jason Shepherd, the study's senior author and a professor of neurobiology at University of Utah Health. "For someone with early-onset Alzheimer's or dementia, if we could stop the spread, then we could prevent further damage and cognitive decline."
The researchers also detected extracellular vesicles containing both Arc and Tau in human brain tissue, suggesting the same mechanism operates in people. However, they emphasized that the work remains preliminary. Most experiments have been conducted in mice, and human studies would be necessary before any therapy could reach patients.
"We have some clues that whatever is happening in these mice could also be happening in humans, but we don't know that yet," Shepherd said. "We're far away from saying that we're developing a treatment for anything. But it could open new avenues to get to that point."
Author Jessica Williams: "This is a clever reframing of Alzheimer's as a problem of cellular trafficking rather than just protein accumulation, and if the mechanism holds in humans, it could genuinely change how we approach the disease."
Comments